Withus Pharmaceutical 2026 Folk Ssireum Uiseong Garlic Championship Tournament Opens in Uiseong, Gyeongbuk on the 31st
Predicted impact: Low
Withus Pharmaceutical위더스제약
330350 · KOSDAQ · ₩330350 · 위더스제약
₩6,450▲ ₩50 (0.78%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y −3.87%
- Market cap
- ₩85B
- Enterprise value
- ₩83B
- P/E
- 15.1×
- P/B
- 0.8×
- Dividend yield
- 0.0%
- ROE
- 5.4%
- Net margin
- 5.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−46.0% from the high
₩5,910Today: ₩6,380 – ₩6,540₩11,950
Returns
- 1W−6.0%
- 1M−11.4%
- 3M+7.1%
- 6M−28.9%
- YTD−25.2%
- 1Y−3.9%
- Volume today
- 37,107
- 0.8× the 20-day average
- Traded today
- ₩239M
- Listed shares
- 13,199,680
- EPS (12 months)
- ₩427
- Earnings yield 6.6%
AI research · InitiationWithus Pharmaceutical: Modest Profits, Low Multiples and a Wide Model RangeThe data shows a small company with growing sales but thinner margins, modest returns and low multiples against its own history.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
- MomentumWeak-9.9% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Withus Pharmaceutical stock overview
Withus Pharmaceutical (위더스제약, KRX: 330350) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean pharmaceutical manufacturer focused on ETC (prescription) finished drugs, with its own production facilities for its main products. Its shares closed at ₩6,450 on Oct 28, 2026, up 0.78% on the day, giving it a market value of ₩85B.
Key facts
- Market cap
- ₩85B
- Sector
- Biotech & Pharma
- Latest price change
- +0.78%
- As of
- Oct 28, 2026
- Main business
- The company is a Korean pharmaceutical manufacturer focused on ETC (prescription) finished drugs, with its own production facilities for its main products.
Quick answers about Withus Pharmaceutical
- What does Withus Pharmaceutical do?
- The company is a Korean pharmaceutical manufacturer focused on ETC (prescription) finished drugs, with its own production facilities for its main products. It concentrates on cardiovascular, musculoskeletal, digestive, antibiotic and central nervous system medicines aimed at aging-related and chronic diseases, and sells through a nationwide sales network. Its cardiovascular products, including the generic cholesterol drug Atorenjeong and the blood pressure drug Vdipin, are key revenue sources, and it also runs a contract manufacturing (CMO) business for its main products.
- What is the market cap of Withus Pharmaceutical?
- The market capitalisation of Withus Pharmaceutical was ₩85B at the close on Oct 28, 2026.
- Who are the largest shareholders of Withus Pharmaceutical?
- According to the latest official filings, the largest reported holders are Seong Dae-yeong (53.01%, as of Nov 20, 2024); Kwon Gwang-yeong (0.40%, as of Nov 20, 2024).
- When is the next earnings report from Withus Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Withus Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company is a Korean pharmaceutical manufacturer focused on ETC (prescription) finished drugs, with its own production facilities for its main products. It concentrates on cardiovascular, musculoskeletal, digestive, antibiotic and central nervous system medicines aimed at aging-related and chronic diseases, and sells through a nationwide sales network. Its cardiovascular products, including the generic cholesterol drug Atorenjeong and the blood pressure drug Vdipin, are key revenue sources, and it also runs a contract manufacturing (CMO) business for its main products.
Written by AI from the company's latest annual report.
- Korean name
- 위더스제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 성대영
- Founded
- Aug 2004
- Listed
- Jul 2020
- Listed shares
- 13,199,680
- Fiscal year ends
- Month 12
- Website
- withuspharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Annual general meeting resultsMar 26, 2026
- Audit report submittedMar 18, 2026
- Annual report (Dec 2025)Mar 18, 2026
Titles in Korean until English translations are added.
Also known as: Withus Pharmaceutical / 위더스제약 / 330350 / KRX:330350
Source: KRX statistical information